AU2014302694B2 - Use of NK-1 receptor antagonist serlopitant in pruritus - Google Patents

Use of NK-1 receptor antagonist serlopitant in pruritus Download PDF

Info

Publication number
AU2014302694B2
AU2014302694B2 AU2014302694A AU2014302694A AU2014302694B2 AU 2014302694 B2 AU2014302694 B2 AU 2014302694B2 AU 2014302694 A AU2014302694 A AU 2014302694A AU 2014302694 A AU2014302694 A AU 2014302694A AU 2014302694 B2 AU2014302694 B2 AU 2014302694B2
Authority
AU
Australia
Prior art keywords
serlopitant
pharmaceutically acceptable
pruritus
polymorph
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014302694A
Other languages
English (en)
Other versions
AU2014302694A1 (en
Inventor
James W. Larrick
Andrew J. Perlman
Edward F. Schnipper
Xiaoming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yarrow Bioscience Inc
Original Assignee
Menlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc filed Critical Menlo Therapeutics Inc
Publication of AU2014302694A1 publication Critical patent/AU2014302694A1/en
Assigned to MENLO THERAPEUTICS INC. reassignment MENLO THERAPEUTICS INC. Amend patent request/document other than specification (104) Assignors: Tigercat Pharma, Inc.
Application granted granted Critical
Publication of AU2014302694B2 publication Critical patent/AU2014302694B2/en
Priority to AU2020200259A priority Critical patent/AU2020200259A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014302694A 2013-06-24 2014-06-24 Use of NK-1 receptor antagonist serlopitant in pruritus Ceased AU2014302694B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200259A AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 2013-06-24
US61/838,784 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200259A Division AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Publications (2)

Publication Number Publication Date
AU2014302694A1 AU2014302694A1 (en) 2016-01-07
AU2014302694B2 true AU2014302694B2 (en) 2019-10-17

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014302694A Ceased AU2014302694B2 (en) 2013-06-24 2014-06-24 Use of NK-1 receptor antagonist serlopitant in pruritus
AU2020200259A Abandoned AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200259A Abandoned AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (enExample)
JP (2) JP2016523260A (enExample)
KR (1) KR20160023692A (enExample)
CN (1) CN105473138A (enExample)
AU (2) AU2014302694B2 (enExample)
BR (1) BR112015031724A2 (enExample)
CA (1) CA2915474A1 (enExample)
HK (1) HK1223820A1 (enExample)
IL (1) IL243189A0 (enExample)
MX (2) MX366728B (enExample)
PH (2) PH12015502777A1 (enExample)
RU (1) RU2666219C2 (enExample)
WO (1) WO2014209962A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
JP2009500452A (ja) 2005-07-11 2009-01-08 メルク エンド カムパニー インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法
WO2007044296A2 (en) 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
EP2141992A1 (en) 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Also Published As

Publication number Publication date
MX2015017763A (es) 2016-06-21
BR112015031724A2 (pt) 2017-07-25
RU2666219C2 (ru) 2018-09-06
KR20160023692A (ko) 2016-03-03
JP2016523260A (ja) 2016-08-08
EP3013336A1 (en) 2016-05-04
CN105473138A (zh) 2016-04-06
CA2915474A1 (en) 2014-12-31
HK1223820A1 (zh) 2017-08-11
RU2015154037A (ru) 2017-07-28
PH12015502777A1 (en) 2016-03-21
IL243189A0 (en) 2016-02-29
PH12020500255A1 (en) 2021-02-22
MX366728B (es) 2019-07-22
WO2014209962A1 (en) 2014-12-31
MX2019008643A (es) 2019-09-10
AU2014302694A1 (en) 2016-01-07
AU2020200259A1 (en) 2020-02-06
JP2019142960A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
AU2020200259A1 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
MX2015004162A (es) Usos novedosos.
EP3829572A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired